{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:49:56Z","timestamp":1789177796485,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.berh.2019.101463","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T09:55:50Z","timestamp":1576749350000},"page":"101463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"title":["Antiphospholipid syndrome"],"prefix":"10.1016","volume":"34","author":[{"given":"Lisa R.","family":"Sammaritano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.101463_bib1","series-title":"Antiphospholipid syndrome: current research highlights and clinical insights","first-page":"3","article-title":"History of antiphospholipid antibody","author":"Lockshin","year":"2017"},{"key":"10.1016\/j.berh.2019.101463_bib2","first-page":"621","article-title":"A\u00a0hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus","volume":"31","author":"Conley","year":"1952","journal-title":"J\u00a0Lab Clin Invest"},{"key":"10.1016\/j.berh.2019.101463_bib3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.101463_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.berh.2019.101463_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib6","series-title":"Antiphospholipid syndrome: current research highlights and clinical insights","first-page":"247","article-title":"Treatment of non-criteria manifestations in antiphospholipid syndrome","author":"Ugolini-Lopes","year":"2017"},{"key":"10.1016\/j.berh.2019.101463_bib7","series-title":"Antiphospholipid syndrome: current research highlights and clinical insights","first-page":"279","article-title":"15th international congress on antiphospholipid antibodies task force on antiphosphlipid syndrome classification report","author":"Zuily","year":"2017"},{"key":"10.1016\/j.berh.2019.101463_bib8","series-title":"Antiphospholipid syndrome: current research highlights and clinical insights","first-page":"171","article-title":"Clinical and prognostic significance of non-criteria antiphospholipid antibody tests","author":"Bertolaccini","year":"2017"},{"key":"10.1016\/j.berh.2019.101463_bib9","series-title":"Antiphospholipid syndrome: current research highlights and clinical insights","first-page":"147","article-title":"Definition and epidemiology of antiphospholipid syndrome","author":"Unlu","year":"2017"},{"key":"10.1016\/j.berh.2019.101463_bib10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.101463_bib11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib12","first-page":"1","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0961203307083316","article-title":"Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus","volume":"16","author":"Martinez-Berriotxoa","year":"2007","journal-title":"Lupus"},{"issue":"61","key":"10.1016\/j.berh.2019.101463_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"15","author":"Tektonidou","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.101463_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A\u00a0cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib16","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody\u2013positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.081194","article-title":"Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus","volume":"36","author":"Danowski","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101463_bib18","first-page":"1560","article-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals","volume":"31","author":"Gir\u00f3n-Gonz\u00e1lez","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101463_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ard.2006.067314","article-title":"Assessment of the 2006 revised antiphospholipid syndrome classification criteria","volume":"66","author":"Kaul","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2019.101463_bib20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","volume":"295","author":"Lim","year":"2006","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2019.101463_bib21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","article-title":"Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101463_bib22","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.berh.2019.101463_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib24","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/rheumatology\/kev238","article-title":"Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study","volume":"54","author":"Zuily","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib25","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib26","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case\u2013control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib27","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2003-01-0320","article-title":"Antiphospholipid\/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study","volume":"102","author":"Gris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.berh.2019.101463_bib28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jri.2010.03.007","article-title":"Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for Factor V Leiden","volume":"85","author":"Manuck","year":"2010","journal-title":"J\u00a0Reprod Immunol"},{"key":"10.1016\/j.berh.2019.101463_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1196\/annals.1422.056","article-title":"Uterine artery velocity waveforms as predictors of pregnancy outcome in patients with antiphospholipid syndrome: a review","volume":"1108","author":"De Carolis","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2019.101463_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/OGX.0b013e3181c97809","article-title":"Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?","volume":"65","author":"Alijotas-Reig","year":"2010","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.berh.2019.101463_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101463_bib33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Antithrombotic Trialists'(ATT) Collaboration: aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2019.101463_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2019.101463_bib35","series-title":"Antiphospholipid syndrome: current research highlights and clinical insights","first-page":"223","article-title":"Prevention and treatment of thrombotic antiphospholipid syndrome","author":"Crowther","year":"2017"},{"key":"10.1016\/j.berh.2019.101463_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib37","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1001\/archinte.160.13.2042","article-title":"Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis","volume":"160","author":"Wahl","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.berh.2019.101463_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","article-title":"Task force of the EULAR standing committee for international clinical studies including therapeutics. EULAR recommendations for the management of systemic lupus erythematosus","volume":"67","author":"Bertsias","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib40","first-page":"622","article-title":"Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus","volume":"32","author":"Mok","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101463_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2011.153817","article-title":"Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case\u2013control study","volume":"71","author":"Martinez-Zamora","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib42","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2011-09-381913","article-title":"Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study","volume":"119","author":"Gris","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.berh.2019.101463_bib43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/1471-0528.15469","article-title":"Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for clinical trials and international networking clinical database and Repository: a retrospective study","volume":"126","author":"de Jes\u00fas","year":"2019","journal-title":"BJOG An Int J Obstet Gynaecol"},{"issue":"6","key":"10.1016\/j.berh.2019.101463_bib44","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C","article-title":"High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin","volume":"44","author":"Erkan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.101463_bib47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.101463_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A\u00a0comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.101463_bib49","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A\u00a0randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib50","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.291.5.576","article-title":"Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke","volume":"291","author":"Levine","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.berh.2019.101463_bib51","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","article-title":"A\u00a0systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","volume":"57","author":"Ruiz-Irastorza","year":"2007","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.101463_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1160\/TH08-06-0384","article-title":"Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort","volume":"101","author":"Neville","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib54","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/ard.2008.093179","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients","volume":"68","author":"Cervera","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7150\/ijms.7.15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2010","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.berh.2019.101463_bib56","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood advances"},{"key":"10.1016\/j.berh.2019.101463_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/key340","article-title":"Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome","volume":"58","author":"Ohnishi","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0961203315617538","article-title":"Patients with antiphospholipid syndrome and thrombotic recurrences: a real world observation (the Piedmont cohort study)","volume":"25","author":"Bazzan","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2019.101463_bib59","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.berh.2019.101463_bib60","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.berh.2019.101463_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.berh.2019.101463_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1suppl","key":"10.1016\/j.berh.2019.101463_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0961203396005001051","article-title":"Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2019.101463_bib64","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib65","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101463_bib66","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A\u00a0randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.101463_bib67","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti\u2013\u03b22-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib68","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in\u00a0vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"L\u00f3pez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib70","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A\u00a0prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101463_bib71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203317716787","article-title":"Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies","volume":"27","author":"Watanabe","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2019.101463_bib72","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib73","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Best practices clinical guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1759720X14554793","article-title":"Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome","volume":"7","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2019.101463_bib75","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1177\/0961203318768890","article-title":"Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment","volume":"27","author":"Di\u00f3szegi","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2019.101463_bib76","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.101463_bib77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.berh.2019.101463_bib78","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V128.22.2603.2603","article-title":"Management of catastrophic antiphospholipid syndrome with eculizumab","volume":"128","author":"Chitalia","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.berh.2019.101463_bib79","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1172\/JCI91300","article-title":"Prevention of preeclampsia","volume":"126","author":"Grotegut","year":"2016","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.berh.2019.101463_bib80","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.berh.2019.101463_bib81","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2019.101463_bib82","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody\u2013associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.berh.2019.101463_bib83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kep373","article-title":"Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression","volume":"49","author":"Mak","year":"2009","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2019.101463_bib84","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","author":"Empson","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2019.101463_bib85","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.10957","article-title":"Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies","volume":"48","author":"Triolo","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0002-9378(00)70500-X","article-title":"Pregnancy Loss Study Group. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy","volume":"182","author":"Branch","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.berh.2019.101463_bib87","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1632388","article-title":"Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study","volume":"47","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.berh.2019.101463_bib88","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipid antibody\u2013related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.berh.2019.101463_bib89","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.berh.2019.101463_bib90","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101463_bib91","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.berh.2019.101463_bib92","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40136","article-title":"Antiphospholipid syndrome and pregnancy: pathogenesis to translation","volume":"69","author":"Abrahams","year":"2017","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.berh.2019.101463_bib93","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"Lefkou","year":"2016","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.berh.2019.101463_bib94","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.berh.2019.101463_bib95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jri.2016.03.004","article-title":"Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study","volume":"115","author":"Ruffatti","year":"2016","journal-title":"J\u00a0Reprod Immunol"},{"issue":"11","key":"10.1016\/j.berh.2019.101463_bib96","doi-asserted-by":"crossref","first-page":"e6338","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.berh.2019.101463_bib97","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A\u00a0pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101463_bib98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.101463_bib99","first-page":"2006","article-title":"Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator","volume":"29","author":"Burcoglu-O'Ral","year":"2002","journal-title":"J\u00a0Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219301597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219301597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:33Z","timestamp":1761499173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219301597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1521694219301597"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.101463","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.101463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101463"}}